ApoE facilitates the microglial response to amyloid plaque pathology
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
One of the hallmarks of Alzheimer’s disease is the presence of extracellular diffuse and fibrillar plaques predominantly consisting of the amyloid-β (Aβ) peptide. Apolipoprotein E (ApoE) influences the deposition of amyloid pathology through affecting the clearance and aggregation of monomeric Aβ in the brain. In addition to influencing Aβ metabolism, increasing evidence suggests that apoE influences microglial function in neurodegenerative diseases. Here, we characterize the impact that apoE has on amyloid pathology and the innate immune response in APPPS1ΔE9 and APPPS1-21 transgenic mice. We report that Apoe deficiency reduced fibrillar plaque deposition, consistent with previous studies. However, fibrillar plaques in Apoe-deficient mice exhibited a striking reduction in plaque compaction. Hyperspectral fluorescent imaging using luminescent conjugated oligothiophenes identified distinct Aβ morphotypes in Apoe-deficient mice. We also observed a significant reduction in fibrillar plaque–associated microgliosis and activated microglial gene expression in Apoe-deficient mice, along with significant increases in dystrophic neurites around fibrillar plaques. Our results suggest that apoE is critical in stimulating the innate immune response to amyloid pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3. Decreased plaque-associated microgliosis in Apoe-deficient mice. (A) Representative images of APPPS1 and Apoe−/−;APPPS1 mice stained with Iba1 to label microglia and X-34 to label amyloid plaques. (B) Significant reduction in the number of microglia in Apoe−/−;APPPS1 (0.60 ± 0.04, n = 7 mice) mice compared with APPPS1 (1.7 ± 0.12, n = 7) within 15 µm (t[12] = 8.3, P < 0.0001) and 30 µm (2.5 ± 0.18, n = 7 mice versus 4.5 ± 0.28, n = 7 mice); t(12) = 5.9, P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APPPS1 (154.3 ± 7.1, n = 7 mice) compared with Apoe−/−;APPPS1 (150.7 ± 14.9, n = 7 mice) was not significantly different; t(12) = 0.22, P = 0.83, Student’s t test. (C) Representative images of APPPS1ΔE9 and Apoe−/−;APPPS1ΔE9 mice stained with Iba1 and X-34. (D) Significant reduction in the number of microglia within 15 µm of Apoe−/−;APPPS1ΔE9 (1.2 ± 0.17, n = 7 mice), compared with APPPS1ΔE9 (2.2 ± 0.1, n = 11 mice); t(16) =5.6, P < 0.0001, Student’s t test, and within 30 µm (2.8 ± 0.24, n = 7 mice) compared with (4.6 ± 0.16, n = 11 mice); t(16) = 6.5, P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APPPS1ΔE9 (160.3 ± 14.7, n = 11 mice) and Apoe−/−;APPPS1ΔE9 (133.2 ± 8.5, n = 7 mice) were not significantly different; t(16) = 1.4, P = 0.19, Student’s t test. (E) Selected differentially expressed inflammatory gene expression from APPPS1 (n = 6 mice) and Apoe−/−;APPPS1 mice (n = 7 mice). See Table S1 for p-values. (F) Analysis of cytokine levels in the hippocampus of APPPS1 and Apoe−/−;APPPS1 mice. Apoe−/−;APPPS1 mice (n = 13 mice) exhibited a significant reduction in CCL3 compared with APPPS1 mice (n = 11 mice). P < 0.0001, Student’s t test. Bars, 100 µm. ***, P < 0.001.](https://figures.cochat.ai/paper-figures/18ed3f387eff4ebda9af8d5233d33033/apoe-facilitates-the-microglial-response-to-amyloid-plaque-pathology-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that neurites surrounding amyloid plaques are enriched in the lysosomal marker, lysosome-associated membrane protein 1 (LAMP1) in both human patients with dementia and mouse models of AD29,30.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as TREM2 has been demonstrated to be an ApoE receptor116–119.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia form a critical interface between APOE genotype and amyloid pathology, mediating A β clearance and restricting local toxicity 25,40 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE also markedly accelerates amyloid deposition (23,24) as well as taumediated neurodegeneration in mouse models (25).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [24]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“3 G; Table S1; Keren-Shaul et al., 2017).”
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 3×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“ApoE expression is low in microglia in a homeostatic activation state, but is strongly up-regulated by neurodegenerative insults (Butovsky et al., 2014, 2015; Krasemann et al., 2017).”
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 1×
“…plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et al., 2016; Jay et al., 2017; Song et al., 2017; Ulland et al., 2017).”
Self-citationCNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 2×
“Tg2576 mice exhibited a roughly 1:5 ratio of Aβ42/Aβ40 in young animals, compared with an ∼1:1 ratio in APP PS1 and APP PS1ΔE9 mice, which likely results in the accelerated development of Aβ-deposition in APP PS1 and APP PS1ΔE9 mice and the formation of amyloid (Jankowsky et al., 2004; Radde et al., 2006).”
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 2×
“20171265 1053 provide additional insight into potential mechanisms underlying our observations (Saito et al., 2014).”
Influential
Cited by
Items 201–300 of 303
Apolipoprotein E loss of function: Influence on murine brain markers of physiology and pathology
Buchanan, H. M., Hull, C. E., Barraza, M. C., Delibegović, M., & Platt, B. (2022) · Aging Brain · doi:10.1016/j.nbas.2022.100055 · Cited by 8
“Previous studies utilising ApoE / animals crossed with Ab-transgenic models suggested that ApoE facilitates [4,66] but is not required [15] for Ab fibrillization and deposition.”
BackgroundKim, B., Tate, M. D., Karahan, H., Wijeratne, H. R. S., Sharify, A. D., Wang, S. S., Kim, J. R., Al-Amin, M. M., Hartigan, K., Chung, S., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.03.011 · Cited by 6
Wijesinghe, P., Li, H. R., Ai, Z., Campbell, M., Chen, S. X., Xi, J., Pham, W. N., & Matsubara, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1495615 · Cited by 7
Sulfonylureas target the neurovascular response to decrease Alzheimer’s pathologyPreprint
Macauley, S. L., Stanley, M., Caesar, E. E., Moritz, W. R., Bice, A. R., Cruz‐Diaz, N., Carroll, C. M., Day, S. M., Grizzanti, J., Mahan, T. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.11.455969 · Cited by 6
Self-citationComparative gene regulatory networks modulating APOE expression in microglia and astrocytesPreprint
Brase, L., Yu, Y., McDade, E., Dominantly Inherited Alzheimer Network (DIAN), Harari, O., & Benítez, B. A. (2024) · medRxiv · doi:10.1101/2024.04.19.24306098 · Cited by 8
Lee, B. H., Cevizci, M., Lieblich, S. E., & Galea, L. A. M. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00694-8 · Cited by 5
“Furthermore, APOEε4 genotype is associated with increased amyloid deposition and dysfunction of the medial temporal lobe, features related to AD [8–10].”
Characterizing the metabolomes of microglia, astrocytes and neurons in ageing and Alzheimer’s brains
Yu, J. K., Li, F., Chen, X.-J., Mou, C., Yao, D., Bi, Z., Chen, X. G., Du, L., Feng, Z., Zhang, X., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01910-2 · Cited by 11
Swaminathan, P., Klingstedt, T., Theologidis, V., Gram, H., Larsson, J. N. K., Hagen, L., Liabakk, N., Gederaas, O. A., Hammarström, P., Nilsson, K. P. R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212458 · Cited by 7
Self-citationHuang, R., Lin, B.-B., Lu, Z., Hao, Y., Li, C. F., Lin, Z., Zhang, Y., Wei, N., & Chen, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770509 · Cited by 5
Joshi, R., Brezáni, V., Mey, G. M., Guixé‐Muntet, S., Ortega‐Ribera, M., Zhuang, Y., Zivny, A., Werneburg, S., Gracia‐Sancho, J., & Szabó, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.08.582968 · Cited by 5
Neurodegeneration as a dysregulation of neuroimmune crosstalk
Bennett, F. C., Hong, S. Y., Jiang, N. J., & Marazzi, I. (2026) · Cell · doi:10.1016/j.cell.2026.07.015 · Cited by 3
“107,108 Microglia have also been implicated in the spread of A β pathology beyond individual plaque niches.”
Vanherle, S., Janssen, A., de Ravé, M. G., Janssen, B., Lodder, C., Lucena, P. B., Kessels, S., Hardy, J., Vandeput, E., Wang, Y., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03036-7 · Cited by 5
“APOE modulates amyloid pathology in amyloid only models by altering amyloid plaque seeding [28, 39], plaque compaction, and microglial association with plaques [32, 37, 39 – 44].”
Self-citationElrahman, H. G. A., Ramadan, A., Saleh, E. M. R. M., Saleh, A. A., Sabry, N. A., & Mohamed, M. R. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2020-0135 · Cited by 3
“A previous study reported that there is a APOE4 carrier of age 95 years old who has no obvious signs of dementia [16].”
BackgroundAnti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brainPreprint
Butler, P. M., Francis, A., Meunier, A. L., Anderson, A. K., Hennessey, E. L., Miller, M. B., Lemere, C. A., Selkoe, D. J., & Stern, A. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.20.654902 · Cited by 4
The APOE Gene Cluster in Normal Aging
Florczak‐Wyspianska, J., Hurła, M., Pikor, D., Poszwa, J., Korczowska-Łącka, I., Szymanowicz, O., Pluto-Prądzyńska, A., Goutor, U., Wiszniewska, M., Kozubski, W. P., et al. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin36401 · Cited by 3
Chen, F., Wang, H., & He, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0297319 · Cited by 2
New Insights into Microglia as Therapeutic Targets in Alzheimer’s Disease
Mandlik, D. S., Mandlik, S. K., & Choudhary, H. B. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230427100702 · Cited by 2
Wybitul, M., Buchmann, A., Langer, N., Höck, C., Treyer, V., & Gietl, A. F. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.03.007 · Cited by 2
A bibliometric analysis of the immune system and cognitive impairment: trends from 1985 to 2024
Zou, B., Xiang, J., Zhang, M., Huang, J., & Feng, C. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1587575 · Cited by 3
Girardi, C. S., Yi, L., Fitz, N. F., Gelain, D. P., Lefterov, I. M., & Koldamova, R. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052435 · Cited by 2
“APOE also regulates microglial interaction with A β and plays a crucial role in plaque compaction [53,54].”
Rosene, M. J., Hsu, S., You, S. F., Brase, L., Verbeck, A. C., Martinez, R. J., Wallace, C. E., Li, Z., Yan, P., Dräger, N. M., et al. (2022) · medRxiv · doi:10.1101/2022.01.31.22270175 · Cited by 2
Self-citationSORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain
Huang, H., Shi, C. H., Yang, W., Piña-Crespo, J. C., Bhatnagar, J., Curatolo, J., Murad, R., Shah, P., Campos, A., Houser, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed6825 · Cited by 1
“Murine Apoe deletion reduced A β deposition in various transgenic APP mouse models ( 82 – 86 ), and expression of human ApoE4 is seen to exacerbate pathological features including tau pathology, ventricle dilation, and glial activation ( 42 ).”
Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
Мазеркина, И. А. (2025) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2025-13-1-7-19 · Cited by 1
Peyvand, P., Allami, P., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0025 · Cited by 1
Mirkamali, A., & Jahromi, S. R. (2025) · Russian Journal of Genetics · doi:10.1134/s1022795425700425 · Cited by 1
“Though the molecular mechanisms through which ε 4 allele increase AD risk are not entirely characterized, it is assumed that APOE affects neurofibrillary tau tangles formation [11] and amyloid beta (A β ) plaques clearance [12].”
Basak, S., Colafrancesco, A. M., Hernandez, R. D., Wei, X., McMeekin, L. J., Dang, D., Simmons, M., Browning, J. L., Noel, K., Zhou, F., et al. (2025) · Glia · doi:10.1002/glia.70112 · Cited by 3
Protective mutations associated with APOE in Alzheimer’s disease
Ma, Y., Li, Y., Wu, G., Liu, L., Tian, M., Han, X., Chen, X., Xuan, X., Zheng, T., Gao, X., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03496-5 · Cited by 1
“This disruption may stabilize a more apoE3-like conformation, enhancing lipidation ef fi ciency, reducing aggregation propensity, and attenuating pathological binding to amyloid-β and neuronal receptors such as TREM2 [87].”
Koivumäki, M., Martiskainen, H., Takalo, M., Lehtisalo, J., Ngandu, T., FinnGen, Snellman, A., Hiltunen, M. O., & Rinne, J. O. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01984-y · Cited by 2
“APOEε4 does not only influence Aβ accumulation but also directly modulates microglial function [28, 38, 47].”
Anti‐amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain
Bjørnholm, K. D., Butler, P. M., Francis, A. E., Varma, C., Spooner, E., Grenon, M. B., Xu, Y. R., Tao, Y., Meunier, A. L., Anderson, A. K., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71350 · Cited by 2
Multiscale Approximations to Understand the Complex Role of Microglia in Alzheimer's Disease
Martínez-Tazo, P., Mejias‐Ortega, M., López-López, V., Bhojwani-Cabrera, A. M., Saxton, E., Canals, S., Hardingham, G. E., Gutiérrez, A., López‐Atalaya, J. P., & Santis, S. D. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70536 · Cited by 2
“This material may subsequently be released under cellular stress, acting as a seed for extracellular amyloid deposition (Kim et al. 2012; Ulrich et al. 2018; Bassil et al. 2021; Kaji et al. 2024).”
Li, E., Zhang, P., & Feng, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783786 · Cited by 6
“TREM2-related programs support microglial lipid handling, metabolic fi tness, and responses to amyloid pathology, whereas ApoE can facilitate the microglial response to plaques and in fl uence innate immune signaling (29, 30).”
Cruz-Sesé, J., Miron-Alcala, M., Alfonso-Triguero, M., Olalde, J., Ruiz, L., Galbis-Gramage, N., Cortés, L., Escobar, L., Preman, P., Snellinx, A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117803 · Cited by 2
Associação entre os aspectos genéticos e imunológicos na patogênese do Alzheimer
Rodrigues, J. M., & Soares, L. S. (2022) · Revista Neurociências · doi:10.34024/rnc.2022.v30.14098 · Cited by 26
EDXRF and the relative presence of K, Ca, Fe and as in amyloidogenic tissues
Ihsan, N. S. M. N., Sani, S. F. A., Looi, L., Pathmanathan, D., Cheah, P., Chiew, S.-F., & Bradley, D. A. (2023) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2023.123743 · Cited by 1
Jacquemin, C. (2023) · theses.fr (ABES) · doi:10.70675/574d02aaz56daz485fz843dz68565d474db9 · Cited by 1
Chen, K., Chen, Y., Ren, Y., Wang, Z., Huang, Y., Pan, M., Li, Z., Casey, M. C., Qiao, W., Shi, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78407-x
Self-citationAstrocytic APOE3-Christchurch expression ameliorates brain amyloid-β pathology in 5xFAD mice
Raulin, A.-C., Alnobani, A., Rodriguez-Martinez, P., Lee, E., Linares, C., Yslas, A. R., Li, M., Ren, Y., Doss, S. V., Roy, B., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04002-9
“All other data are available from the corresponding author upon reasonable request.”
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
Self-citationModelling the neurobiology of Alzheimer’s disease in vitro
Muñoz, S. S. (2019) · Research Online (University of Wollongong)
Rôle des récepteurs P2X4 dans la dégradation d’ApoE : implication dans la maladie d’Alzheimer
Hua, J. (2019) · theses.fr (ABES) · doi:10.70675/9a24edbdzd1fbz4cecza5eaz617931d6db22
Regulation and Function of TREM2-dependent Pathways in Neurodegeneration
Song, W. M. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/vfgz-nm61
Self-citationThe Role of Apolipoprotein E in Alzheimer Disease: From Therapy to Mechanism
Huynh, T. V. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/4axz-tr29
Koch, B. M. E. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7716
“However, using a more aggressive AD model with additional mutation within γ-secretase subunit PSEN1, ApoE ablation did not reduce Aβ load as strongly as in the previously described models (Ulrich et al., 2018).”
BackgroundPerspective Chapter: Alzheimer - A Complex Genetic Background
Calabrò, M., & Crisafulli, C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101455
Kipnis, J., & Mesquita, S. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734935594.793556877
APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice
Valencia‐Olvera, A. C., Balu, D., Moore, A., Shah, M., Ainis, R., Xiang, B., Saleh, Y., Cai, D., LaDu, M. J., & Tai, L. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231210
Xu, G. M., Sacilotto, P., Gorski, C., Bali, P., Fromholt, S., Vo, Q., McFarland, K. N., Lu, Q., Borchelt, D., & Chakrabarty, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.30.591932
The biochemical pathways of Alzheimer's disease
El-Gammal, M. A., & Kodous, F. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00001-4
ApoE and Brain Synaptic Dynamics
Huang, Z. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_68-1
Wang, Y., Ma, X., Cen, H., Wang, J., Wu, J., Ding, D., Xiao, Y., & Zhao, Q. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70104 · Cited by 1
“48,49 Existing literature has also reported the associationbetween APOE ε 4andRNFLthickness.”
Self-citationWang, N., Wang, M., Jeevaratnam, S., Rosenberg, C. L., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622301
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618616
Self-citationAdditional file 1 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608512
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618622
Self-citationAdditional file 2 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608515
Additional file 10 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608542
Wang, N., Wang, M., Jeevaratnam, S., Rosenberg, C. L., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622304
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A., DeGrado, W. F., & Condello, C. (2021) · Figshare · doi:10.6084/m9.figshare.17696286
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618631
Self-citationAdditional file 7 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608530
Eskandari‐Sedighi, G., Crichton, M. C., Zia, S., Gomez‐Cardona, E., Cortez, L. M., Patel, Z. H., Takahashi, K., St. Laurent, C. D., Sidhu, G., Sarkar, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26725883
Hashimoto, T., Fujii, D., Naka, Y., Kashiwagi‐Hakozaki, M., Matsuo, Y., Matsuura, Y., Wakabayashi, T., & Iwatsubo, T. (2020) · Figshare · doi:10.6084/m9.figshare.13346572
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A., DeGrado, W. F., & Condello, C. (2021) · Figshare · doi:10.6084/m9.figshare.17696280
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618628
Self-citationAdditional file 5 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608524
Additional file 4 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608521
Wang, N., Wang, M., Jeevaratnam, S., Rosenberg, C. L., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622307
Additional file 3 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608518
Farfara, D., Sooliman, M., Avrahami, L., Royal, T. G., Amram, S., Rozenstein‐Tsalkovich, L., Trudler, D., Blanga‐Kanfi, S., Eldar-Finkelman, H., Pahnke, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.26606671
Farfara, D., Sooliman, M., Avrahami, L., Royal, T. G., Amram, S., Rozenstein‐Tsalkovich, L., Trudler, D., Blanga‐Kanfi, S., Eldar-Finkelman, H., Pahnke, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26606674
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618634
Self-citationXiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618619
Self-citationWang, N., Wang, M., Jeevaratnam, S., Rosenberg, C. L., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622310
Additional file 6 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608527
Wang, N., Wang, M., Jeevaratnam, S., Rosenberg, C. L., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622298
Wang, N., Wang, M., Jeevaratnam, S., Rosenberg, C. L., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622295
Additional file 9 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608539
Snellman, A., Ekblad, L. L., Tuisku, J., Koivumäki, M., Ashton, N. J., Lantero‐Rodriguez, J., Karikari, T. K., Helin, S., Bucci, M., Löyttyniemi, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22620676
Additional file 8 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608536
Ontrafelen van de rol van APOE in astrocyten en microglia bij de ziekte van Alzheimer
Preman, P. (2023) · Lirias (KU Leuven)
The cholesteryl transfer protein and apolipoprotein E in Alzheimer's disease models
Efrem, S. (2019) · eScholarship@McGill (McGill) · doi:10.82308/26189
Soni, N. (2023) · eScholarship (California Digital Library)
The Dementia Cascade: From the Preclinical Stage
Chen, Q., Xu, J., Gao, H., & Cai, H. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_1
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
Investigating the physiological function of the amyloid precursor protein in Drosophila melanogaster
Kesisoglou, E. (2020) · theses.fr (ABES) · doi:10.70675/691831c4z5491z4cb9zb88az10456e67b7ce
Single-cell transcriptomics of human brain disorders
Arbabi, K., Carito, G., Luquez, T., & Wainberg, M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03573-9 · Cited by 1
“However, GWAS implicated microglia as primary mediators of neurodegenerative disease risk, particularly in Alzheimer ’ s disease, highlighting genes involved in lipid metabolism and phagocytosis [4 – 6].”
Targeting microglia: A new strategy for the treatment of Alzheimer's disease
Zheng, M., Yang, M., Su, W., Tian, L., & Gao, W. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.578966
Chen, H., Lin, Y. Y., Kang, D., & Zhao, T. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261462546 · Cited by 1
“19,20 Aberrant activation of the innate immune system accelerates A β deposition and the progression of neurodegeneration.”
Kim, D., Kim, Y. S., & Jeong, B. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70288
“17,18 Notably, amyloid-responsive microglia are significantly reduced in brains carrying APOE ε 4 or TREM2 R47H variants, 19 and ε 4-expressing microglia exhibit altered lipid metabolism relative to ε 3-expressing counterparts in mouse models.”
Cholesterol at the Center of Alzheimer’s Disease: A Unifying Hypothesis on the Pathogenic Mechanism
Zhu, B. T. (2026) · Molecules · doi:10.3390/molecules31142418
DeepPlaque: a scalable multimodal platform for Aβ pathology and cell analysis in Alzheimer’s disease
Wong, H. Y., Jin, C., Yuen, S. L., Yang, X., Gill, S. S., Xu, J., Lai, K. P. E., Fu, W., Gao, W., Wang, X., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00488-4
“Concordant with previous fi ndings (Bales et al, 1997; Namba et al, 1991; Ulrich et al, 2018; Boon et al, 2020; Sakono and Zako, 2010; Finder and Glockshuber, 2007), the expressions of APOE (apolipoprotein E) and APP (amyloid precursor protein) were signi fi cantly higher in core A β plaques than in…”
Gergian, C., Urbanaviciute, P., Wells, P. M., Transfeld, J. L., Askarova, A., Yaa, R. M., Wu, Y., Ziegler, K. C., Nickl, C. K., Pasillas, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.09.750356
“In alignment, APOE alleles have been linked to amyloid pathology, cholesterol metabolism 70,71 , and phagocytosis 60 ; and MS4A4A to negative regulation of TREM2 signalling, lipid metabolism and a chemokine microglial cell state 72,73 .”
Astrocytic synapse engulfment is differentially controlled by APOE genotype
Sekizar, S., Holt, K., Meyers, S., Tzioras, M., King, D., Tulloch, J., Jackson, R. J., & Spires‐Jones, T. L. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.09.026
Dysfunction of lipid metabolism and lysosomal capacity: at the core of microglial aging?
Šimončičová, E., & Tremblay, M. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1884230
“Under physiological conditions, microglia are not significant producers of APOE in the CNS compared to astrocytes (Ulrich et al., 2018) and the murine LDAM signature was similarly not associated with ApoE regulation (Marschallinger et al., 2020).”
Wong, H. T., Gleason, C., Boylan, A., Adler, M. J., Kosoy, R., Fullard, J. F., Levendosky, E., Hoffman, G. E., Molina, H., Roussos, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.25.754430
“APOE also influences microglia activation, potentially regulating the innate immune response to Aβ-plaques (Corder et al., 1993, Krasemann et al., 2017, Farrer et al., 1997, Keren-Shaul et al., 2017, Ulrich et al., 2018, Kosoy et al., 2025).”
Jeskanen, H. (2026) · UEF eRepo (University of Eastern Finland)
Metadata
- Authors
- Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., Stewart, F. R., Anderson, E., Wang, Y., Colonna, M., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Linköping University (SE)
- Radboud University Nijmegen (NL)
- Eli Lilly (United States) (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-02-26
- Volume
- 215
- Issue
- 4
- Pages
- 1047-1058
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5881464
- OpenAlex
- W2790949074
- Cited by
- 297
- References
- 58
- Citations by year
- 2026: 26 · 2025: 29 · 2024: 41 · 2023: 46 · 2022: 44 · 2021: 33 · 2020: 31 · 2019: 32 · 2018: 15
- FWCI
- 19.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (AG047644)
- JPB Foundation
- Cure Alzheimer’s Fund
- NIH (RF1AG05148501, 5-T32CA009547-30)
- Donors Cure Foundation (CCAD201703)
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- apolipoprotein E, amyloid-beta, amyloid plaques, microglia, Alzheimer's disease, innate immune response, microglial activation, ApoE-deficient mice, dystrophic neurites
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Apolipoproteins E, Brain, Disease Models, Animal, Humans, Immunity, Innate, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.